New basic approach to treat non-small cell lung cancer based on RNA-interference

Thoracic Cancer

Volumn 5, Issue 2, 2014, Pages 112-120

  Makowiecki, Christina ^a   Nolte, Andrea ^a   Sutaj, Besmire ^a   Keller, Timea ^a   Avci Adali, Meltem ^a   Stoll, Heidi ^a   Schlensak, Christian ^a   Wendel, Hans Peter ^a   Walker, Tobias ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hypoxia inducible factors; Lung cancer; RNA interference; siRNA; STAT3

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER GROWTH; CASY CELL COUNTER; CELL GROWTH; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 84895094175     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12065     Document Type: Article

References (30)

1. Azzoli CG, Baker S Jr, Temin S etal. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
2. Andersen S, Donnem T, Stenvold H etal. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS ONE 2011; 6 (8): e23847.
3. Stenvold H, Donnem T, Andersen S etal. Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer 2012; 75: 235-241.
4. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391 (6669): 806-811.
5. Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs 2010; 24: 183-194.
6. Alderton GK. Therapy: A big step for targeting RNAs. Nat Rev Cancer 2010; 10: 313.
7. Davis ME, Zuckerman JE, Choi CH etal. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464 (7291): 1067-1070.
8. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 2009; 1: 142-151.
9. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007; 117: 3623-3632.
10. Kim WY, Perera S, Zhou B etal. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009; 119: 2160-2170.
11. Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P. Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis 2012; 29: 615-624.
12. Chiavarina B, Whitaker-Menezes D, Migneco G etal. HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9: 3534-3551.
13. Kamlah F, Eul BG, Li S etal. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009; 16: 195-205.
14. Pawlus MR, Wang L, Ware K, Hu CJ. Upstream stimulatory factor 2 and hypoxia-inducible factor 2alpha (HIF2alpha) cooperatively activate HIF2 target genes during hypoxia. Mol Cell Biol 2012; 32: 4595-4610.
15. Onishi A, Chen Q, Humtsoe JO, Kramer RH. STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. Exp Cell Res 2008; 314: 377-386.
16. Takeda K, Noguchi K, Shi W etal. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 1997; 94: 3801-3804.
17. Walker T, Nolte A, Steger V etal. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection. Eur J Cardiothorac Surg 2013; 43: 628-634.
18. Bozcuk H, Abali H, Coskun S. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World J Surg Oncol 2012; 10: 161.
19. Liao WY, Chen JH, Wu M etal. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer 2013; 14: 418-424.
20. Lyseng-Williamson KA. Erlotinib: a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations. Mol Diagn Ther 2013; 17: 57-62.
21. Favier J, Lapointe S, Maliba R, Sirois MG etal. HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer 2007; 7: 139.
22. Hanna SC, Krishnan B, Bailey ST etal. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013; 123: 2078-2093.
23. Yadav A, Kumar B, Datta J, Teknos TN, Kumar P etal. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 2011; 9: 1658-1667.
24. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006; 66: 3162-3168.
25. Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006; 6: 107-121.
26. Kusaba T, Nakayama T, Yamazumi K etal. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006; 15: 1445-1451.
27. Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer 2006; 5: 15.
28. Nolte A, Aufderklamm S, Scheu K etal. Small interfering RNA transfection against serum response factor mediates growth inhibition of benign prostatic hyperplasia fibroblasts. Nucleic Acid Ther 2013; 23: 62-70.
29. Nolte A, Walker T, Schneider M etal. Small-interfering RNA-eluting surfaces as a novel concept for intravascular local gene silencing. Mol Med 2011; 17: 1213-1222.
30. Nolte A, Raabe C, Walker T, Simon P, Ziemer G, Wendel HP. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides 2009; 19: 141-150.